The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is Wave of FDA Warning Letters to Injectable Compounders in Q1 2014 Follows 2013 Inspection Blitz and Legislative Empowerment; Reci FDA Moves on Peptides: What Compounding Pharmacies Need to Know FDA Compliance for Peptide Therapy and BPC 157 Holt Law FDA Is Diving Deeper in GMP Compliance for Compounding Pharmacies A Follow up Lachman Consultant Services, Inc.